[59th Annual Meeting of the Society of Biological Psychiatry. April 29-May 1, 2004, New York, New York, USA].

A. Borkowska,J. Rybakowski

Psychiatria Polska

Abstract:

What problem does this paper attempt to address?

Cannabidiol Treatment for Adult Patients with Drug‐Resistant Epilepsies: A Real‐World Study in a Tertiary Center

Quentin Calonge,Aurore Besnard,Laurent Bailly,Maria Damiano,Phintip Pichit,Sophie Dupont,Isabelle Gourfinkel‐An,Vincent Navarro

DOI: https://doi.org/10.1002/brb3.70122

IF: 3.1

2024-11-07

Brain and Behavior

Abstract:We extracted all adult patients treated at our tertiary center with cannabidiol for pharmacoresistant epilepsy, with a follow‐up of at least 1 year, and evaluated the efficacy and retention based on the indication. We found similar efficacy and retention rates in patients with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex compared to other forms of pharmacoresistant epilepsy. Background and purpose Around 30% of patients with epilepsy show drug‐resistant epilepsy (DRE). While cannabidiol has demonstrated efficacy as an adjunctive treatment in Dravet syndrome (DS), Lennox–Gastaut Syndrome (LGS), and epilepsy related to tuberous sclerosis complex (TSC), its more global effectiveness in adult patients with DRE apart from these three specific contexts needs to be clarified. Methods We conducted a retrospective study at the epilepsy unit of Pitié Salpêtrière Hospital. Patients initiating pharmaceutical cannabidiol treatment and followed for at least 1 year were included. Patients were categorized into "authorized" (LGS, DS, or TSC) and "off‐label" groups. Cannabidiol effectiveness and tolerance were compared between groups, and characteristics of responders (patients with >50% reduction in seizure frequency) in the off‐label group were examined. Results Ninety‐one patients, followed by a median duration of 24 months, were included. A total of 35.2% of the patients were in the authorized group. No significant differences were observed in responder rates between groups (31.3% vs. 35.6%, p = 0.85) and retention rates at 1 year (75.0% vs. 74.6%, p = 0.97). Sleepiness was more commonly reported in the authorized group (50.0% vs. 22.0%, p = 0.01), with no other significant differences. Among off‐label patients (n = 59), clobazam co‐prescription was more prevalent in responders (71.4% vs. 28.9%, p = 0.002). Conclusion Our findings suggest that cannabidiol may benefit all adult patients with DRE, particularly those already receiving clobazam. Randomized controlled trials are warranted in off‐label patients to validate these observational findings.

behavioral sciences,neurosciences
Assessing the quality of Swedish health economics research

M. Drummond,G. Botten,U. Häkkinen,K. M. Pedersen

DOI: https://doi.org/10.1080/14034940601086646

2006-12-01

Scandinavian Journal of Public Health

Abstract:The sub-discipline of health economics has grown rapidly over the last ten years. Swedish researchers were among the first in the field and have featured prominently in its development. Therefore the review of Swedish Health Economics Research, commissioned by FAS (the Swedish Council for Working Life and Social Research) published as a supplement to this journal [1], provided an excellent opportunity to take stock of past achievements and to make recommendations for the future. The first task of the evaluation group was to define what is meant by ‘health economics’. This is not a straightforward task, as health economics is closely associated with social medicine and public health, with many studies being undertaken by multidisciplinary teams. In the end the evaluation group opted for the definition outlined by Williams (1987), shown in Figure 3.1 of the supplement. This considers health economics to consist of eight areas of research, including theoretical topics, such as ‘what is health?’ and applied topics, such as ‘microeconomic evaluation at the treatment level’. However, one caveat was applied; namely, the research in any of the eight areas had to adopt a theoretical and/or empirical perspective consistent with the parent discipline (economics). The methods applied by the evaluation group comprised three elements. First, an inventory of Swedish health economics research was compiled by surveying those university research units, government and non-government agencies thought to be active in the field. (Private, for profit, organisations such as pharmaceutical companies were excluded.) Secondly, a bibliometric analysis of the Swedish health economics literature from 1986 to 2004 was conducted. Finally, face-to-face interviews were held with representatives of the main health economics research groups and the main users of research, such as national and regional governments. The inventory survey, conducted by Marianne Hanning, found that health economics research was undertaken in many parts of Sweden, with the largest concentrations of researchers being in Stockholm, Lund/Malmo and Linkoping. Some researchers were based in economics departments, others in medical schools, with successful research being undertaken in either location. The bibliometric analysis, conducted by Olle Persson, showed that the publication record of Swedish researchers had been impressive, with Sweden ranked fifth in the world in publications in the top ranked journals in the field. (The normal position of Sweden in such surveys is rank 12.) The bibliometric maps, shown in Figures 5.1 and 5.2 of the supplement, also illustrate the ways in which Swedish researchers have collaborated with one another and with researchers from other countries. The research groups were also asked to identify their five ‘best’ publications, in terms of methodological contribution or policy impact, and the PhD students they had supervised. This showed that, although research had been conducted in all the 8
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US

Tristan T Sands,Shahryar Rahdari,Michael S Oldham,Eduardo Caminha Nunes,Nicole Tilton,Maria Roberta Cilio

DOI: https://doi.org/10.1007/s40263-018-0589-2

CNS Drugs

Abstract:Background: Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox-Gastaut and Dravet syndromes, but most published studies have not extended beyond 12-16 weeks. Objective: The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods: Patients aged 1-17 years with refractory epilepsy were enrolled in an open-label prospective study through individual patient and expanded access programs between April 2013 and December 2014. Seizure types were video-electroencephalogram confirmed prior to enrollment. After a 28-day evaluation period, during which baseline seizure frequency was assessed, cannabidiol was given as add-on therapy at 5 mg/kg/day and titrated weekly by 5-mg/kg increments to a dose of 25 mg/kg/day. Blood tests were performed at baseline, after 1, 2, and 3 months, and every 3 months thereafter. Trough concentrations of concomitant antiepileptic drugs were measured at baseline, after 1, 2, and 3 months of therapy, and as clinically indicated afterwards. Concomitant antiepileptic drugs, ketogenic diet ratio, and vagal nerve stimulator settings remained unchanged during the baseline period and the first 3 months of treatment, unless there was a significant increase in plasma concentrations. Seizure frequency was reported daily in seizure diaries by parents or caregivers. Clinical assessments occurred after 15 days of treatment, at 1 month, at 3 months, and every 3 months thereafter. Diaries of seizure frequency and adverse events were reviewed at each visit. The primary efficacy outcome was a reduction in seizure frequency and responders were defined as those patients achieving a > 50% reduction in motor seizures. Results: Twenty-six children were enrolled. Most had genetic epilepsies with daily or weekly seizures and multiple seizure types. All were refractory to prior antiepileptic drugs (range 4-11, mean 7), and were taking two antiepileptic drugs on average. Duration of therapy ranged from 4 to 53 months (mean 21 months). Adverse events were reported in 21 patients (80.8%), including reduced appetite in ten (38.4%), diarrhea in nine (34.6%), and weight loss in eight (30.7%). Four (15.4%) had changes in antiepileptic drug concentrations and three had elevated aspartate aminotransferase and alanine aminotransferase levels when cannabidiol was administered together with valproate. Serious adverse events, reported in six patients (23.1%), included status epilepticus in three, catatonia in two, and hypoalbuminemia in one. Fifteen patients (57.7%) discontinued cannabidiol for lack of efficacy, one because of status epilepticus, and one for severe weight loss. The retention rate declined rapidly in the first 6 months and more gradually thereafter. At 24 months, the number of patients continuing cannabidiol as adjunctive therapy was nine of the original 26 (34.6%). Of these patients, seven (26.9%) had a sustained > 50% reduction in motor seizures, including three (11.5%) who remain seizure free. Conclusion: Over a 4-year period, cannabidiol was effective in 26.9% of children with otherwise refractory epilepsy. It was well tolerated in about 20% of patients, but 80.8% had adverse events, including 23.1% with serious adverse events. Decreased appetite and diarrhea were frequent along with weight loss that became evident only later in the treatment.
Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study

Cristian Eduardo Navarro

DOI: https://doi.org/10.1007/s10072-022-06393-1

2022-09-21

Neurological Sciences

Abstract:Abstract IntroductionThe safety and efficacy of a formulation high in cannabidiol (CBD) and low in ∆9-tetrahydrocannabinol (THC) to treat drug-resistant epilepsy have been examined previously in children, but not in adult population. The aim of this study was to evaluate whether CBD-rich oil, as an add-on treatment to conventional antiepileptic drugs, was effective, safe, and well-tolerated in adults with drug-resistant focal epilepsy (DRFE).MethodsAn open-label, prospective cohort, single-center in adult patients with DRFE, were receiving stable doses of antiepileptic drugs (AEDs). A cannabisbased-magistral formulation (CBMF) (100 mg/ml CBD and THC <1.9 mg/ml) wasadministrated 0.1 ml sublingually every 12 hours, up-titrated weekly. Theprimary outcome was to establish a reduction in seizures frequency >50% at12 weeks. Adverse-drug reactions monitoring was done. p-value <0.05 wasstatistically significant.ResultsBetweenAugust 2020 and July 2022, 44 (38.6%) patients completed >3 months offollow-up. The median daily dose of CBD was 200 mg, that of THC was 4 mg, andthat of CBD per kilogram of weight was 3.7 mg. The median number of seizuresper month before CBD treatment was 11, and after CBD treatment was 2.5(p<0.001). A reduction in seizures >50% at 12 week was achieved in 79.5%of the patients. The median percentage change in seizure frequency per monthwas 84.1% at 12 weeks. Five patients reported any adverse-drug reactions.ConclusionThe CBMF is a highly effective and safety therapy to treat adult patients with DRFE. The reduction in seizures frequency is maintained over time.

neurosciences,clinical neurology
Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy

Nicola Pietrafusa,Alessandro Ferretti,Marina Trivisano,Luca de Palma,Costanza Calabrese,Giusy Carfì Pavia,Ilaria Tondo,Simona Cappelletti,Federico Vigevano,Nicola Specchio

DOI: https://doi.org/10.1007/s40272-019-00341-x

Abstract:Background: A pharmaceutical grade formulation of cannabidiol (CBD) has been approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome; however, this formulation is not yet available to patients outside the USA. In addition, CBD is thought to have broad anti-seizure properties that may be beneficial for other types of intractable epilepsy. Objective: The aim of this study was to evaluate the efficacy, safety and tolerability of artisanal medical CBD oil in patients with developmental and epileptic encephalopathy (DEE) at the tertiary epilepsy center of Bambino Gesù Children's Hospital in Rome, Italy. Methods: This was a single-center, prospective, open-label study. Patients aged from 1 to 18 years with DEE and seizures refractory to appropriate antiepileptic drugs (AEDs) and other alternative treatments (i.e., vagal nerve stimulator and ketogenic diet) were included. Crystalline extract CBD powder (98-99% pure) in an oil artisanal formulation was added to the baseline AED regimen at a dosage of 2-5 mg/kg/day divided for twice-daily administration, then up-titrated until intolerance or a maximum dosage of 25 mg/kg/day was reached. Patients were treated for at least 6 months. Efficacy, safety and tolerability of CBD treatment were assessed through the evaluation of seizure frequency and reports of adverse effects. Results: Twenty-nine patients were enrolled in this study (41.4% male). The mean duration of exposure to artisanal CBD was 11.2 months [range 6-25 months; standard deviation (SD) ± 4.4 months]. Mean age at study enrollment was 9.3 years (range 1.9-16.3 years; SD ± 4.7 years). Eleven out of 29 patients (37.9%) had a ≥ 50% improvement in seizure frequency; one patient became seizure free. None of the patients reported worsening seizure frequency; however, 18 patients (62.1%) experienced no beneficial effect regarding seizure frequency. Adverse effects were reported in seven patients (24.14%), most commonly somnolence, decreased appetite and diarrhea. Adverse events were mild and transient, and no dose modification of CBD or other AEDs was required. Conclusions: These data suggest that CBD may have beneficial effects in patients with DEE and an acceptable safety profile. Placebo-controlled randomized trials should be conducted to formally assess the safety and efficacy of CBD in patients with DEE.
Is adjunctive Cannabidiol effective in controlling seizures for adult patients with Lennox-Gastaut Syndrome? - A single centre long term follow up study

Maha Elbadri,Smriti Bose,Mohammed Elkider,Tom Hayton,Dougall McCorry,Salini Sumangala,Barbara Wysota,Shanika Samarasekera

DOI: https://doi.org/10.1016/j.yebeh.2024.109904

Abstract:Epileptic encephalopathies are a disabling and life-limiting cause of childhood-onset epilepsy. Lennox Gastaut syndrome (LGS) is a characteristic example. In spite of the development of multiple medical and surgical therapies, many patients with these conditions remain treatment refractory Cannabidiol was licenced by The National Institute for Health and Care Excellence (NICE) in December 2019 for the adjunctive treatment of seizures associated with Lennox Gastaut syndrome [TA 615]. As the largest complex epilepsy centre in the Midlands, we describe our findings from a single centre retrospective study in 50 adults (aged 16 and over) with LGS- associated epilepsy. Our outcome measure was the efficacy of Cannabidiol on seizures of differing types over a 6-24-month period. Patients were treated with adjunctive Cannabidiol (with Clobazam, as per NICE recommendations). Each patient's usual anti-seizure medications (ASMs) were continued. Patients with a Vagal Nerve Stimulator (VNS) in situ remained on this treatment. Gradual titration of Cannabidiol from 1 mg/kg/day up to 10 mg/ kg/ day reduced the frequency of both focal and generalised seizures with ≥ 50 % seizure reduction in 76 % of the cohort. No patients became seizure free. Cannabidiol was well tolerated; 94 % of the cohort remained on the drug at last follow up.
Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain

J J García-Peñas,A Gil Nagel-Rein,R Sánchez-Carpintero,V Villanueva-Haba

DOI: https://doi.org/10.33588/rn.73S01.2021250

2021-09-10

Abstract:Introduction: Cannabidiol (CBD) is one of the main components of the cannabis plant that has demonstrated anti-epileptic seizure effect. Following its clinical development, in September 2019 the European Medicines Agency approved its indication for the adjunctive therapy of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), combined with clobazam (CLB), in patients of 2 years of age and older. Aim: To establish recommendations on the use of plant-derived highly purified CBD on which Spanish experts have reached consensus for the treatment of epilepsy in patients with DS and LGS based on their clinical experience and the scientific evidence. Development: Consensus meeting with the participation of four Spanish neurologists and neuropediatric who are experts in epilepsy secondary to DS and LGS and with clinical experience in the use and management of CBD. They discussed on several topics, including posology (starting dose, dose escalation schema), efficacy (assessment of outcomes and indications for treatment withdrawal), and safety (evaluation, drug-drug interactions, adverse events management). Conclusions: In order to optimise CBD treatment, a slow dose escalation (= 4 weeks) is recommended until the maximum recommended dose or the desire effect is reached. It is also recommended that the concomitant antiseizure medications (ASMs) be reduced in case of adverse events due to interactions, and that the treatment continues for at least 6 months if it is well tolerated. The efficacy and safety of CBD must be assessed individually, considering the benefits and risks for individual patients.
Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

Simona Lattanzi,Gaetano Zaccara,Emilio Russo,Angela La Neve,Monica Anna Maria Lodi,Pasquale Striano

DOI: https://doi.org/10.1080/14737175.2021.1834383

Abstract:Introduction: Pharmaceutically purified oral cannabidiol (CBD) has been recently approved by the US Food and Drug Administration and European Medicines Agency as treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), which are severe and difficult-to-treat developmental and epileptic encephalopathies with onset in early childhood. Areas covered: This review will critically review the pharmacokinetic properties of CBD, the interactions with antiseizure and non-antiseizure medications, and the main tolerability and safety issues to provide guidance for its use in everyday practice. Expert opinion: CBD is metabolized in the liver and can influence the activity of enzymes involved in drug metabolism. The best characterized drug-drug interaction is between CBD and clobazam. The most common adverse events include somnolence, gastrointestinal discomfort, and increase in serum transaminases. High-grade purified CBD oral solution represents an effective therapeutic option in patients with DS and LGS. The findings cannot be extrapolated to other cannabis-based products, synthetic cannabinoids for medicinal use and non-medicinal cannabis and CBD derivatives.
Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program

Arie Weinstock,E Martina Bebin,Daniel Checketts,Gary D Clark,Jerzy P Szaflarski,Laurie E Seltzer,Elizabeth A Thiele,Farhad Sahebkar

DOI: https://doi.org/10.1002/epi4.13013

Epilepsia Open

Abstract:Objective: The cannabidiol (CBD) Expanded Access Program provided compassionate access to CBD for patients with treatment-resistant epilepsy, including tuberous sclerosis complex (TSC), at 35 US epilepsy centers. Here, we present the long-term efficacy and safety outcomes for add-on CBD treatment in patients with TSC. Methods: Patients received plant-derived, highly purified CBD (Epidiolex® 100 mg/mL, oral solution), increasing from 2 to 10 mg/kg/d to tolerance or maximum of 25-50 mg/kg/d. Efficacy endpoints were percentage change from baseline in median monthly convulsive, focal, and total seizure frequency and ≥ 50%, ≥75%, and 100% responder rates across 12-week visit windows through 144 weeks. Adverse events (AEs) are reported through 233 weeks. Results: Thirty-four patients with confirmed TSC were included. Mean age was 12.4 years (range, 1.8-31.2), and patients were receiving a median of 3 (range, 1-7) antiseizure medications (ASMs) at baseline. Median CBD dose was 25-28 mg/kg/d for 36 weeks and then 20-50 mg/kg/d through 228 weeks. Dose reduction from baseline occurred for most ASMs, except topiramate. Median reduction in the frequency of convulsive, focal, and total seizures was 44%-81%, 51%-87%, and 44%-87%, respectively, through 144 weeks. Responder rates (≥50%, ≥75%, and 100% reduction) were 43%-71%, 14%-58%, and 0%-25% for convulsive seizures; 52%-75%, 35%-60%, and 7%-32% for focal seizures; and 46%-79%, 26%-65%, and 0%-13% for total seizures. A total of 94% of patients experienced ≥1 AE; 47% had serious AEs, considered treatment unrelated by the investigator. Treatment-related AEs (TRAEs) occurred in 71% of patients. The most frequently reported TRAEs were somnolence, diarrhea, and ataxia. Two patients experienced AEs leading to discontinuation. There were no deaths. Significance: Long-term add-on CBD use was associated with reduced seizure frequency through 144 weeks. The safety profile was consistent with previous reports. Plain language summary: In this study, we evaluated efficacy and safety of cannabidiol (CBD) treatment in patients with tuberous sclerosis complex receiving CBD in addition to other antiseizure treatments in an Expanded Access Program. After starting CBD, 46%-79% of patients had at least 50% reduction and 26%-65% had at least 75% reduction in the number of seizures per month; up to 13% had no seizures through 144 weeks. Safety results were similar to prior studies; sleepiness and diarrhea were common treatment-related side effects. These results show that long-term CBD treatment was associated with fewer seizures and mild/moderate side effects.
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

Michal Tzadok,Shimrit Uliel-Siboni,Ilan Linder,Uri Kramer,Orna Epstein,Shay Menascu,Andrea Nissenkorn,Omer Bar Yosef,Eli Hyman,Dorit Granot,Michael Dor,Tali Lerman-Sagie,Bruria Ben-Zeev

DOI: https://doi.org/10.1016/j.seizure.2016.01.004

IF: 3.414

Seizure

Abstract:Purpose: To describe the experience of five Israeli pediatric epilepsy clinics treating children and adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil. Methods: A retrospective study describing the effect of cannabidiol (CBD)-enriched medical cannabis on children with epilepsy. The cohort included 74 patients (age range 1-18 years) with intractable epilepsy resistant to >7 antiepileptic drugs. Forty-nine (66%) also failed a ketogenic diet, vagal nerve stimulator implantation, or both. They all started medical cannabis oil treatment between 2-11/2014 and were treated for at least 3 months (average 6 months). The selected formula contained CBD and tetrahydrocannabinol at a ratio of 20:1 dissolved in olive oil. The CBD dose ranged from 1 to 20mg/kg/d. Seizure frequency was assessed by parental report during clinical visits. Results: CBD treatment yielded a significant positive effect on seizure load. Most of the children (66/74, 89%) reported reduction in seizure frequency: 13 (18%) reported 75-100% reduction, 25 (34%) reported 50-75% reduction, 9 (12%) reported 25-50% reduction, and 19 (26%) reported <25% reduction. Five (7%) patients reported aggravation of seizures which led to CBD withdrawal. In addition, we observed improvement in behavior and alertness, language, communication, motor skills and sleep. Adverse reactions included somnolence, fatigue, gastrointestinal disturbances and irritability leading to withdrawal of cannabis use in 5 patients. Conclusions: The results of this multicenter study on CBD treatment for intractable epilepsy in a population of children and adolescents are highly promising. Further prospective, well-designed clinical trials using enriched CBD medical cannabis are warranted.
Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects

Krithiga Sekar,Alison Pack

DOI: https://doi.org/10.12688/f1000research.16515.1

2019-02-28

F1000Research

Abstract:Medically refractory epilepsy remains an area of intense clinical and scientific interest since a significant porportion of patients continue to suffer from debilitating seizures despite available therapies. In this setting, recent studies have focused on assessing the benefits of cannabidiol (CBD)-enriched cannabis, a plant based product without psychoactive properties which has been shown to decrease seizure frequency in animal models. More recently, several randomized controlled and open label trials have studied the effects of Epidiolex, a 99% pure oral CBD extract, on patients with refractory epilepsy. This in turn has led to the FDA approval of and more recently, to the Drug Enforcement Administration’s placement of Epidiolex into schedule V of the Controlled Substances Act (CSA). In this review, we summarize the major findings of several recent large-scale studies using this product with a focus on its adverse effects.

English Else
Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

Giovanni Di Mauro,Giovanni Vietri,Loreta Quaranta,Fabio Placidi,Francesca Izzi,Alessandro Castelli,Andrea Pagano,Francesca Leonardis,Viviana De Angelis,Ciro Bianco,Maria Grazia Celeste,Nicola Biagio Mercuri,Claudio Liguori

DOI: https://doi.org/10.2174/0118715273304077240603115521

2024-06-21

Abstract:Introduction: Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment of these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC). Case presentation: Here, we present two cases of effective use of hpCBD in both refractory and super- refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures. Conclusion: According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.
Cannabidiol‐enriched oil for adult patients with drug‐resistant epilepsy: Prospective clinical and electrophysiological study

Sigal Glatt,Sophie Shohat,Mor Yam,Lilach Goldstein,Inbal Maidan,Firas Fahoum

DOI: https://doi.org/10.1111/epi.18025

IF: 6.74

2024-05-30

Epilepsia

Abstract:Objective Cannabidiol‐enriched oil (CBDO) is being used increasingly to improve seizure control in adult patients with drug‐resistant epilepsy (DRE), despite the lack of large‐scale studies supporting its efficacy in this patient population. We aimed to assess the effects of add‐on CBDO on seizure frequency as well as on gait, cognitive, affective, and sleep‐quality metrics, and to explore the electrophysiological changes in responder and non‐responder DRE patients treated with add‐on CBDO. Methods We prospectively recruited adult DRE patients who were treated with add‐on CBDO. Patients were evaluated prior to treatment and following 4 weeks of a maintenance daily dose of ≈260 mg CBD and ≈12 mg Δ9‐tetrahydrocannabinol (THC). The outcome measures included seizure response to CBDO (defined as ≥50% decrease in seizures compared to pre‐CBDO baseline), gait testing, Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS), and sleep‐quality questionnaire assessments. Patients underwent electroencephalography (EEG) recording during rest as well as event‐related potentials (ERPs) during visual Go/NoGo task while sitting and while walking. Results Nineteen patients were recruited, of which 16 finished pre‐ and post‐CBDO assessments. Seven patients (43.75%) were responders demonstrating an average reduction of 82.4% in seizures, and nine patients (56.25%) were non‐responders with an average seizure increase of 30.1%. No differences in demographics and clinical parameters were found between responders and non‐responders at baseline. However, responders demonstrated better performance in the dual‐task walking post‐treatment (p = .015), and correlation between increase in MoCA and seizure reduction (r = .810, p = .027). Post‐CBDO P300 amplitude was lower during No/Go‐sitting in non‐responders (p = .028) and during No/Go‐walking in responders (p = .068). Significance CBDO treatment can reduce seizures in a subset of patients with DRE, but could aggravate seizure control in a minority of patients; yet we found no specific baseline clinical or electrophysiological characteristics that are associated with response to CBDO. However, changes in ERPs in response to treatment could be a promising direction to better identify patients who could benefit from CBDO treatment.

clinical neurology
Cannabidiol Treatment for Refractory Epilepsies in Pediatrics

Umberto Raucci,Nicola Pietrafusa,Maria Chiara Paolino,Giovanni Di Nardo,Maria Pia Villa,Piero Pavone,Gianluca Terrin,Nicola Specchio,Pasquale Striano,Pasquale Parisi

DOI: https://doi.org/10.3389/fphar.2020.586110

IF: 5.6

2020-09-29

Frontiers in Pharmacology

Abstract:Cannabis extracts in oil are becoming increasingly available, and, during the last years, there has been growing public and scientific interest about therapeutic properties of these compounds for the treatment of several neurologic diseases, not just epilepsy. The discovered role of the endocannabinoid system in epileptogenesis has provided the basis to investigate the pharmacological use of exogenously produced cannabinoids, to treat epilepsy. Although, physicians show reluctance to recommend Cannabis extracts given the lack of high-quality safety available data, from literature data cannabidiol (CBD) results to be a promising and safe anticonvulsant drug with low side-effect. In particular, according to early studies, CBD can reduce the frequency of seizures and lead to improvements in quality of life in children affected by refractory epilepsy. So, for these reasons, the detailed study of the interactions between CBD and anticonvulsant drugs (AEDs) administered simultaneously in polytherapy, is arousing increasing interest, to clarify and to assess the incidence of adverse effects and the relation between dose escalation and quality of life measures. To date, in pediatric age, CBD efficacy and safety is not supported by well-designed trials and strong scientific evidence are not available. These studies are either retrospective or small-scale observational and only during the last years Class I evidence data for a pure form of CBD have been available, as demonstrated in placebo-controlled RCTs for patients affected by Lennox-Gastaut syndrome and Dravet syndrome. It is necessary to investigate CBD safety, pharmacokinetics and interaction with other AEDs alongside performing double-blinded placebo-controlled trials to obtain conclusive data on its efficacy and safety in the most frequent epilepsies in children, not just in the epileptic encephalopathy. This review was aimed to revise the available data to describe the scientific evidence for CBD in Pediatric Epilepsies.

pharmacology & pharmacy
CBD in the Treatment of Epilepsy

Kinga Borowicz-Reutt,Julia Czernia,Marlena Krawczyk

DOI: https://doi.org/10.3390/molecules29091981

IF: 4.6

2024-04-26

Molecules

Abstract:It has been several years since highly purified cannabidiol (CBD) was registered as a medication that can be used in children of at least 2 years of age to treat different types of seizures related to Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and more recently tuberous sclerosis complex (TSC). During this time, 39 randomized clinical trials (RCTs) and 13 meta-analyses on the efficacy and safety of CBD treatment have been published. Each of the meta-analyses had its own criteria for the RCTs' inclusion and, therefore, slightly different interpretations of the analyzed data. Each of them contributed in its own way to the understanding of CBD pharmacology, mechanisms of therapeutic action, development of adverse reactions, and drug–drug interactions. Hence, it seemed reasonable to gather the most relevant data in one article and present all the current knowledge on the use of CBD in epilepsy. The results of the 13 meta-analyses presented herein confirmed the effectiveness and safety of CBD in children and adolescents with DREs. In adults, reliable conclusions cannot be drawn due to insufficient data.

chemistry, multidisciplinary,biochemistry & molecular biology
Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects

Alessandra Morano,Martina Fanella,Mariarita Albini,Pierangelo Cifelli,Eleonora Palma,Anna Teresa Giallonardo,Carlo Di Bonaventura

DOI: https://doi.org/10.2147/NDT.S203782

IF: 2.989

2020-02-08

Neuropsychiatric Disease and Treatment

Abstract:Alessandra Morano, 1 Martina Fanella, 1 Mariarita Albini, 1 Pierangelo Cifelli, 2, 3 Eleonora Palma, 2 Anna Teresa Giallonardo, 1 Carlo Di Bonaventura 1 1 Epilepsy Unit, Department of Human Neurosciences, "Sapienza" University of Rome, Rome, Italy; 2 Department of Physiology and Pharmacology, Pasteur Institute-Cenci Bolognetti Foundation, University of Rome Sapienza, Rome, Italy; 3 IRCCS "Neuromed", Pozzilli, IS, Italy Correspondence: Carlo Di Bonaventura Epilepsy Unit, Department of Human Neurosciences, "Sapienza" University of Rome, P.le A. Moro, 5, Rome 00185, Italy Email c_dibonaventura@yahoo.it Cannabidiol (CBD) is one of the prominent phytocannabinoids found in Cannabis sativa , differentiating from Δ 9 -tetrahydrocannabinol (THC) for its non-intoxicating profile and its antianxiety/antipsychotic effects. CBD is a multi-target drug whose anti-convulsant properties are supposed to be independent of endocannabinoid receptor CB 1 and might be related to several underlying mechanisms, such as antagonism on the orphan GPR55 receptor, regulation of adenosine tone, activation of 5HT 1A receptors and modulation of calcium intracellular levels. CBD is a lipophilic compound with low oral bioavailability (6%) due to poor intestinal absorption and high first-pass metabolism. Its exposure parameters are greatly influenced by feeding status (ie, high fat-containing meals). It is mainly metabolized by cytochrome P 450 (CYP) 3A4 and 2C19, which it strongly inhibits. A proprietary formulation of highly purified, plant-derived CBD has been recently licensed as an adjunctive treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), while it is being currently investigated in tuberous sclerosis complex. The regulatory agencies' approval was granted based on four pivotal double-blind, placebo-controlled, randomized clinical trials (RCTs) on overall 154 DS patients and 396 LGS ones, receiving CBD 10 or 20 mg/kg/day BID as active treatment. The primary endpoint (reduction in monthly seizure frequency) was met by both CBD doses. Most patients reported adverse events (AEs), generally from mild to moderate and transient, which mainly consisted of somnolence, sedation, decreased appetite, diarrhea and elevation in aminotransferase levels, the last being documented only in subjects on concomitant valproate therapy. The interaction between CBD and clobazam, likely due to CYP2C19 inhibition, might contribute to some AEs, especially somnolence, but also to CBD clinical effectiveness. Cannabidivarin (CBDV), the propyl analogue of CBD, showed anti-convulsant properties in pre-clinical studies, but a plant-derived, purified proprietary formulation of CBDV recently failed the Phase II RCT in patients with uncontrolled focal seizures. Keywords: cannabidiol, cannabidivarin, phytocannabinoids, epileptic encephalopathies, tuberous sclerosis complex, drug-resistance

psychiatry,clinical neurology
Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations

Mohamed Osman,Jamileh Khalil,Mostafa El-Bahri,Jamal Swalah Mcdahrou,Reem Fahda,Reymin Mustafa,Arthur Ooi,Marwa Attayee,Rachelle Catanzariti,Lisa Pont,Kylie Williams,Stewart Yeung,Kamal Dua,Gabriele De Rubis,Raimar Loebenberg

DOI: https://doi.org/10.1016/j.cbi.2024.110988

IF: 5.168

2024-04-05

Chemico-Biological Interactions

Abstract:Epilepsy is a neurological disorder characterized by overstimulation of neurotransmitters and uncontrolled seizures. Current medications for epilepsy result in adverse effects or insufficient seizure control, highlighting the necessity to develop alternative therapies. Cannabidiol (CBD), derived from cannabis plants, has been popularly explored as an alternative. CBD is shown to have anti -convulsivatng and muscle-relaxing properties, which have been used in patients with epilepsy with promising results. Current research explores varying dosages in either adult or paediatric patients, with little or no comparison between the two populations. In this review, we aim at consolidating this data and comparing the effect and pharmacokinetic properties of CBD across these two patient populations. When comparing the absorption, there was insufficient data to show differences between paediatric and adult patients. Similarly, limited information was available in comparing the distribution of CBD, but a higher volume of distribution was found in the paediatric population. From the metabolism perspective, the paediatric population had a greater success rate when treated with the drug compared to the adult population. In the elimination, there were no clear distinctions in the clearance rate between the two populations. The drug's half-life was highly variable in both populations, with paediatrics having a lower range than adults. In summary, the paediatric population had a more significant reduction in the severity of seizures compared to the adult population upon CBD treatment. The complexity in which CBD operates highlights the need for further studies of the compound to further understand why differences occur between these two populations.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol

Victoria Evans,Laura Gorham,Zhao Liu,Christopher L. Anderson,Cynthia R. Johnson,Paul R. Carney

DOI: https://doi.org/10.1016/j.yebeh.2021.108325

2021-11-01

Abstract:ObjectiveTo evaluate the effects of oral pharmacological cannabidiol (CBD) on seizures, side effects, quality of life, behavior, mood, and sleep in children with drug-resistant epilepsy (DRE) during a phase II, prospective, open-label clinical study.MethodsDuring a phase II expanded access program (EAP) study to evaluate the safety and efficacy of using cannabidiol (CBD) for the long-term treatment of children with drug-resistant epilepsy, secondary outcome measures were also performed, including quality of life (QOLCE), behavior (aberrant behavior checklist ABC), and sleep (children's sleep habit questionnaire, CSHQ). Participants between the ages of 2 and 16 years of age with drug-resistant epilepsy (n = 35) were included in this EAP. Primary outcomes included change in parent-recorded seizure frequency relative to baseline, as well as the safety and tolerability over the course of 24 months of CBD treatment. Secondary outcomes observed in the first 12 months included changes in child behavior, and cognitive function, and sleep quality.ResultsThe median change in overall seizure frequency decreased from baseline (n = 33) by −61.3% ([n = 33], Inter Quartile Range (IQR): 43–88%) at month 3, −62.9% at month 6 ([n = 29], IQR: 48–92%), −74.7% at month 12 ([n = 29], IQR: 64–96%), and finally −83.7% ([n = 28], IQR: 68–100%) at the conclusion of 24 months of treatment. Seven (20%) of the 35 patients enrolled withdrew from treatment and observation by month 24: 2 failed inclusion criteria at baseline, 4 due to lack of treatment efficacy, and 1 was lost to follow-up. The 12-month recording of secondary measures revealed a significant improvement in Irritability (-39.4%, [n = 28], ABC), Hyperactivity (-45.4%, [n = 28], ABC), Cognition in Quality of Life (+14.2%, [n = 28], QOLCE), Behavioral function (+14.7%, [n = 28], QOLCE), General Health (+14.7%, [n = 28], QOLCE), Sleep duration (–33.9%, [n = 28], CSHQ), Daytime sleepiness (–23.8%, [n = 28], CSHQ), and nocturnal arousals (-36.2%, [n = 28], CSHQ).SignificanceThe results of this phase II open-label study demonstrate that pharmacological CBD significantly reduces seizure frequency, and improves QOL, behavior deficits, and sleep disruption, in children with drug-resistant epilepsy. The results also suggest that CBD is efficacious in controlled seizures over a 2-year period in childhood DRE.

psychiatry,clinical neurology,behavioral sciences
Cannabis Based Drug Shows Promise in Children with Resistant Epilepsy

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.j2564

2017-01-01

BMJ

Abstract:A cannabis based drug has shown encouraging results in treating a form of epilepsy unresponsive to existing drugs.1 Children with Dravet syndrome, a rare and catastrophic form of epilepsy, may experience many seizures a day. The condition, caused in most cases by a known genetic mutation affecting sodium channels in the brain, occurs in one child in 40 000 and leads to developmental damage and long term learning difficulties. Children affected require lifelong care. Anecdotal evidence has suggested that cannabis helps some children, but the new research is the first randomised controlled trial to test the idea. It randomly assigned 120 children aged 2-18 in Europe and the US either to cannabidiol—a purified form of cannabis with very low levels …
Real-World Evidence of Factors Affecting Cannabidiol Exposure in Children with Drug-Resistant Developmental and Epileptic Encephalopathies

Lucas Brstilo,Gabriela Reyes Valenzuela,Roberto Caraballo,Carlos Pérez Montilla,Facundo García Bournissen,Paulo Cáceres Guido,Paula Schaiquevich

DOI: https://doi.org/10.3390/pharmaceutics15082120

IF: 6.525

2023-08-11

Pharmaceutics

Abstract:The identification of factors that affect cannabidiol (CBD) systemic exposure may aid in optimizing treatment efficacy and safety in clinical practice. In this study, we aimed to correlate CBD plasma concentrations at a steady state to demographic, clinical, and pharmacological characteristics as well as seizure frequency after the administration of a purified CBD oil solution in a real-world setting of children with drug-resistant developmental and epileptic encephalopathies (DEEs). Patients receiving oral CBD pharmaceutical products at maintenance were enrolled. Venous blood samples were drawn before the CBD morning dose, 12 h apart from the last evening dose (C0 or CBD trough concentration). A linear mixed-effect analysis was implemented to assess the correlation between C0 and clinical, laboratory, pharmacological, and lifestyle factors. Fifteen females and seven males with a median age of 12.8 years (ranging between 4.7 and 17.2) were included. The median CBD dose was 8.8 mg/kg/day (ranging between 2.6 and 22.5), and the CBD C0 median (range) was 48.2 ng/mL (3.5–366.3). The multivariate model showed a 109.6% increase in CBD C0 in patients with concomitant levothyroxine (β = 0.74 ± 0.1649, p < 0.001), 56.8% with food (β = 0.45 ± 0.1550, p < 0.01), and 116.0% after intake of a ketogenic diet (β = 0.77 ± 0.3141, p < 0.05). All patients included were responders without evidence of an association between C0 and response status. In children with DEEs, systemic concentrations of CBD may be significantly increased when co-administered with levothyroxine, food, or a ketogenic diet.

pharmacology & pharmacy

[59th Annual Meeting of the Society of Biological Psychiatry. April 29-May 1, 2004, New York, New York, USA].

Cannabidiol Treatment for Adult Patients with Drug‐Resistant Epilepsies: A Real‐World Study in a Tertiary Center

Assessing the quality of Swedish health economics research

Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US

Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study

Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy

Is adjunctive Cannabidiol effective in controlling seizures for adult patients with Lennox-Gastaut Syndrome? - A single centre long term follow up study

Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain

Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome

Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects

Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

Cannabidiol‐enriched oil for adult patients with drug‐resistant epilepsy: Prospective clinical and electrophysiological study

Cannabidiol Treatment for Refractory Epilepsies in Pediatrics

CBD in the Treatment of Epilepsy

Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects

Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations

Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol

Cannabis Based Drug Shows Promise in Children with Resistant Epilepsy

Real-World Evidence of Factors Affecting Cannabidiol Exposure in Children with Drug-Resistant Developmental and Epileptic Encephalopathies